Navigation Links
HB-EGF protects intestines from a variety of injuries, pair of studies suggests
Date:8/20/2013

It's not often that one treatment offers therapeutic potential for multiple conditions. However, after more than two decades of research, Gail Besner, MD, principal investigator for the Center for Perinatal Research and pediatric surgeon for the Department of Pediatric Surgery at Nationwide Children's Hospital, and her team have found that this may just be the case with HB-EGF, or heparin-binding EGF-like growth factor.

Having discovered the growth factor in 1990, Dr. Besner most recently conducted two studies in mice published in June in the Journal of Pediatric Surgery that reveal the potential of HB-EGF to protect the intestines from diverse types of injury. The first offers evidence that treatment with the growth factor may help the intestines protect themselves from damage after exposure to radiation therapy.

"Many patients are treated with radiation therapy for pelvic and abdominal cancers each year, and over half suffer from injury to the intestines as a result, which may limit their ability to receive additional therapy," Dr. Besner says. "In the future, treatment with HB-EGF may protect the intestines from this injury, enabling patients to receive more therapy, or at least not suffer as much damage from the radiation."

HB-EGF is a protein that stimulates cells to grow and to move. Cell proliferation and migration are critical to wound healing, including the healing of intestinal wounds. In addition, HB-EGF decreases the production of multiple substances that are formed upon intestinal injury and that would normally act to worsen the injury. This allows the protein to protect the intestine from further harm.

To boost the potential protective potency of HB-EGF, Dr. Besner and her lab directed a second study involving stem cell administration, which is increasingly used to protect organs from injury. "We demonstrated that administration of HB-EGF protects the intestines from injury, and administration of mesenchymal stem cells protects the intestines from injurybut treatment with both therapies simultaneously acts synergistically to further protect the intestines from injury."

Together, the results of the two studies offer Dr. Besner encouragement for a healthier future for her tiny patients. Newborns, especially those born prematurely, are at particular risk of an injury to the intestines known as necrotizing enterocolitis, or NEC. Dr. Besner's research suggests HB-EGF may hold significant clinical potential for these babies.

"The mortality of NEC is too high, despite widespread research on itif I operate on one of these babies, I have to tell the parents that their baby only has a 50 percent chance of living," Dr. Besner says. "Because of this, I am very motivated to find a cure. Mounting work from our laboratory shows that HB-EGF can protect the intestines from NEC. It is our hope that, in the future, we can administer HB-EGF to newborns most at risk of developing NEC in order to prevent them from developing this devastating disease."

Having studied the potential for therapeutic applications of HB-EGF for more than two decades, Dr. Besner is optimistic about the protein's potential. "We have some very exciting new lines of HB-EGF research going on in our laboratory at present, and we feel that the future for HB-EGF use in the treatment of human clinical disease remains bright."


'/>"/>

Contact: Gina Bericchia
Gina.Bericchia@NationwideChildrens.org
614-355-0495
Nationwide Children's Hospital
Source:Eurekalert

Related biology news :

1. Neuroblastoma: Autophagy protects from chemotherapy
2. Parkinsons disease: Parkin protects from neuronal cell death
3. Biodiversity protects against disease, scientists find
4. New park protects 15,000 gorillas
5. Ah, that new car smell: NASA technology protects spacecraft from outgassed molecular contaminants
6. A class of RNA molecules protects germ cells from damage, Penn vet researchers show
7. Strawberry extract protects against UVA rays
8. UN protects wild heart of Central Africa
9. Boosting blood system protein complex protects against radiation toxicity
10. Clemson plant breeders roll out new oat variety
11. Testing method promising for spinal cord injuries, multiple sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2016)... 2016 The Department of Transport Management ... 44 million US Dollar project, for the , ... Personalization, Enrolment, and IT Infrastructure , to ... and implementation of Identity Management Solutions. Numerous renowned international vendors ... Decatur was selected for the most compliant and ...
(Date:5/24/2016)... care by providing unparalleled technology to leaders of the medical imaging industry.  As such, ... to the range of products distributed by Ampronix. Photo - http://photos.prnewswire.com/prnh/20160524/371420 ... ... ... With ...
(Date:5/9/2016)... 9, 2016 Elevay is currently ... expanding freedom for high net worth professionals seeking travel ... globally connected world, there is still no substitute for ... duplicate sealing your deal with a firm handshake. This ... taking advantage of citizenship via investment programs like those ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... ... June 27, 2016 , ... ... findings on what they believe could be a new and helpful biomarker for ... research. Click here to read it now. , Biomarkers are components ...
(Date:6/27/2016)... 27, 2016  Liquid Biotech USA ... of a Sponsored Research Agreement with The University ... (CTCs) from cancer patients.  The funding will be ... correlate with clinical outcomes in cancer patients undergoing ... then be employed to support the design of ...
(Date:6/24/2016)... ... ... While the majority of commercial spectrophotometers and fluorometers use the z-dimension of 8.5 ... end machines that use the more unconventional z-dimension of 20mm. Z-dimension or ... the cuvette holder. , FireflySci has developed several Agilent flow cell product lines ...
(Date:6/23/2016)... , June 23, 2016   Boston Biomedical ... novel compounds designed to target cancer stemness pathways, ... been granted Orphan Drug Designation from the U.S. ... of gastric cancer, including gastroesophageal junction (GEJ) cancer. ... designed to inhibit cancer stemness pathways by targeting ...
Breaking Biology Technology: